Adverum 3-Year Efficacy and Safety Results from Study in Patients with Wet AMD

 

• Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden
• 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3
• Durable aflibercept protein levels up to 4.5 years after a single Ixo-vec IVT injection
• Ixo-vec continues to be generally well tolerated
• Previously announced aflibercept protein levels from the LUNA study were also presented

https://www.biospace.com/article/releases/adverum-biotechnologies-announces-3-year-efficacy-and-safety-results-from-the-optic-extension-study-in-patients-with-wet-amd-at-aao-2023/